AMENDMENTS TO THE CLAIMS

IN THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application. Please amend the claims as follows.

1. (Currently Amended) A compound of Formula (I):



(I)

wherein

m is an integer of from 0 to 3;

n is an integer of from 0 to 3;

R_1 is aryl;

R_2 is

[[a)]] a group of the formula -N(R_9R_{10}), -NHC(O)R_9, or -NHC(O)OR_9;

wherein R_9 and R_{10} are independently selected from the group consisting of

1) –H;

2) –Aryl;

3) -C_{1-6} alkyl;

4) -C_{1-6} alkylaryl;

5)  ;

6) –aryl; and

7) -C_{1-6} alkyl;

R_3 and R_4 are independently selected from the group consisting of

a) H;

b) –aryl;

c) -C_{1-6} alkyl;

d) -C_{1-6} alkylaryl; and

e) -C_{1-6} alkoxyaryl;

R_5, R_6, R_7, and R_8 are independently selected from the group consisting of

a) -H;

b) -C_{1-6} alkyl;

c) –aryl;

d) -C_{1-6} alkylaryl;

e) -C(O)-O-C_{1-6} alkyl;

f) -C(O)-O-C_{1-6} alkylaryl;

g) -C(O)-NH-C_{1-6} alkyl;

h) -C(O)-NH-C_{1-6} alkylaryl;

i) -SO_2-C_{1-6} alkyl;

j) -SO_2-C_{1-6} alkylaryl;

k) -SO_2-aryl;

l) -SO_2-NH-C_{1-6} alkyl;

m) $-SO_2-NH-C_{1-6}$ alkylaryl;

n) $-C(O)-C_{1-6}$ alkyl;

o) $-C(O)-C_{1-6}$ alkylaryl;

p) $-Y-C_{1-6}$ alkyl;

q) -Y-aryl;

r) $-Y-C_{-1-6}$ alkylaryl;

s) $-Y-C_{1-6}$ alkylene-$NR_{13}R_{14}$;

t) $-Y-C_{1-6}$ alkylene-W-R_{15};

wherein Y and W are independently selected from the group consisting of $-CH_2-$, -O-, -N(H), -S-, SO_2-, -CON(H)-, -NHC(O)-, -NHCON(H)-, $-NHSO_2-$, $-SO_2N(H)-$, -C(O)-O-, $-NHSO_2NH-$, -O-CO-,



;

wherein R_{16} and R_{17} are independently selected from the group consisting of aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, and C_1-C_6 alkoxyaryl;

R_{15} is aryl, C_1-C_6 alkyl, or C_1-C_6 alkylaryl; and

u) halogen, hydroxyl, cyano, carbamoyl, and carboxyl;

wherein at least one of R_5, R_6, R_7, and R_8 is $-Y-C_{1-6}$ alkylene-$NR_{13}R_{14}$, and

R_{11}, R_{12}, R_{13}, and R_{14} are independently selected from the group consisting of hydrogen, aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, and C_1-C_6 alkoxyaryl; or

R_{13} and R_{14} are taken together to form a ring having the formula $-(CH_2)_o-X-(CH_2)_p-$ bonded to the nitrogen atom to which R_{13} and R_{14} are attached, and/or R_{11} and R_{12} are taken together to form a ring having the formula $-(CH_2)_o-X-(CH_2)_p-$ bonded to the atoms to which R_{11} and R_{12} are connected, wherein o and p are, independently, 1, 2, 3, or 4; X is a direct bond, $-CH_2-$, -O-, -S-, $-S(O_2)-$, -C(O)-, -CON(H)-, -NHC(O)-, -NHCON(H)-, $-NHSO_2-$, $-SO_2N(H)-$, -C(O)-O-, -O-C(O)-, $-NHSO_2NH-$,



wherein the aryl and/or alkyl group(s) in R_1, R_2, R_3, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11}, R_{12}, R_{13}, R_{14} R_{15}, R_{16}, R_{17}, R_{18}, and R_{19} may be optionally substituted 1-4 times with a substituent group, wherein said substituent group(s) or the term substituted refers to groups selected from the group consisting of:

a) -H;

b) $-Z-C_{1-6}$ alkyl;
$-Z-C_{1-6}$ alkylaryl;
$-Z-C_{1-6}$-alkyl-$NR_{20}R_{21}$;
$-Z-C_{1-6}$-alkyl-W-R_{22};
wherein Z and W are independently selected from the group consisting of $-CH_2-$, -O-, -N(H), -S-, SO_2-, -CON(H)-, -NHC(O)-, -NHCON(H)-, $-NHSO_2-$, $-SO_2N(H)-$, -C(O)-O-, $-NHSO_2NH-$, -O-CO-,



wherein;

R_{22}, R_{23}, and R_{24} are independently selected from the group consisting of aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, and C_1-C_6 alkoxyaryl;

c) halogen, hydroxyl, cyano, and carbamoyl; and

wherein R_{20} and R_{21} are independently selected from the group consisting of hydrogen, aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, and C_1-C_6 alkoxyaryl; or R_{20} and R_{21} are taken together to form a ring having the formula $-(CH_2)_q-X-(CH_2)_r-$ bonded to the nitrogen atom to which R_{20} and R_{21} are attached wherein q and r are, independently, 1, 2, 3, or 4; X is a direct bond, $-CH_2-$, -O-, -S-, $-S(O_2)-$, -C(O)-, -CON(H)-, -NHC(O)-, -NHCON(H)-, $-NHSO_2-$, $-SO_2N(H)-$, -C(O)-O-, -O-C(O)-, $-NHSO_2NH-$,



R_{25}, R_{26}, and R_{27} are independently selected from the group consisting of hydrogen, aryl, C_1-C_6 alkyl, and C_1-C_6 alkylaryl; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

2. (Previously presented) The compound of claim 1, wherein m is an integer of from 0 to 3;

n is 0; R_3 is hydrogen as represented by the formula (II)



(II)

and wherein

R_1 is an aryl group;

R_2 is a group of the formula -N(R_9R_{10}), -NHC(O)R_9, or -NHC(O)OR_9;

wherein R_9 and R_{10} are independently selected from the group consisting of

1) –H;

2) –Aryl;

3) -C_{1-6} alkyl; and

4) -C_{1-6} alkylaryl;

R_4 is

a) H;

b) –aryl;

c) -C_{1-6} alkyl;

d) -C_{1-6} alkylaryl; or

e) -C_{1-6} alkoxyaryl;

R_5, R_6, R_7, and R_8 are independently selected from the group consisting of

a) -H;

b) -C_{1-6} alkyl;

c) –aryl;

d) -C_{1-6} alkylaryl;

e) -C(O)-O-C_{1-6} alkyl;

f) -C(O)-O-C_{1-6} alkylaryl;

g) -C(O)-NH-C_{1-6} alkyl;

h) -C(O)-NH-C_{1-6} alkylaryl;

i) -SO_2-C_{1-6} alkyl;

j) -SO_2-C_{1-6} alkylaryl;

k) -SO_2-aryl;

l) -SO_2-NH-C_{1-6} alkyl;

m) -SO_2-NH-C_{1-6} alkylaryl

n) -C(O)-C_{1-6} alkyl;

o) -C(O)-C_{1-6} alkylaryl;

p) -Y-C_{1-6} alkyl;

q) -Y-aryl;

r) -Y-C_{-1-6} alkylaryl;

s) -Y-C_{1-6} alkylene-$NR_{13}R_{14}$;

t) -Y-C_{1-6} alkylene-W-R_{15};

wherein Y and W are independently selected from the group consisting of -CH_2-, -O-, -N(H), -S-, SO_2-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -$NHSO_2$-, -SO_2N(H)-, -C(O)-O-, -$NHSO_2NH$-, -O-CO-,



;

wherein R_{16} and R_{17} are independently selected from the group consisting of aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, and C_1-C_6 alkoxyaryl;

R_{15} is aryl, C_1-C_6 alkyl, or C_1-C_6 alkylaryl, and

u) halogen, hydroxyl, cyano, carbamoyl, and carboxyl;

wherein at least one of R_5, R_6, R_7, and R_8 is -Y-C_{1-6} alkylene-N-$R_{13}R_{14}$,

R_{13}, and R_{14} are independently selected from the group consisting of hydrogen, aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, and C_1-C_6 alkoxyaryl; or

R_{13} and R_{14} are together to form a ring having the formula -$(CH_2)_o$-X-$(CH_2)_p$- bonded to the nitrogen atom to which R_{13} and R_{14} are attached, wherein o and p are, independently, 1, 2, 3, or 4; X is a direct bond, –CH_2-, -O-, -S-, -$S(O_2)$-, -C(O)-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -$NHSO_2$-, -$SO_2N(H)$-, -C(O)-O-, -O-C(O)-, -$NHSO_2NH$-,



and wherein the aryl and/or alkyl group(s) in R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{13}, R_{14} R_{15}, R_{16}, R_{17}, R_{18}, and R_{19} may be optionally substituted 1-4 times with a substituent group, wherein said substituent group(s) or the term substituted refers to groups selected from the group consisting of:

a) -H;

b) -Z-C_{1-6} alkyl;

-Z-aryl;

-Z-C_{-1-6} alkylaryl;

-Z-C_{1-6}-alkyl-$NR_{20}R_{21}$;

-Z-C_{1-6}-alkyl-W-R_{22};

wherein Z and W are independently selected from the group consisting of -CH_2-, -O-, -N(H), -S-, -SO_2-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -$NHSO_2$-, -$SO_2N(H)$-, -C(O)-O-, -$NHSO_2NH$-, -O-CO-,



;

wherein;

R_{22}, R_{23}, and R_{24} are independently selected from the group consisting of aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, and C_1-C_6 alkoxyaryl;

c) halogen, hydroxyl, cyano, and carbamoyl; and

wherein R_{20} and R_{21} are independently selected from the group consisting of hydrogen, aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, and C_1-C_6 alkoxyaryl; or R_{20} and R_{21} are taken together to form a ring having the formula -$(CH_2)_q$-X-$(CH_2)_r$- bonded to the nitrogen atom to which R_{20} and R_{21} are attached wherein q and r are, independently, 1, 2, 3, or 4; X is a direct bond, –CH_2-, -O-, -S-, -$S(O_2)$-, -C(O)-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -$NHSO_2$-, -$SO_2N(H)$-, -C(O)-O-, -O-C(O)-, -$NHSO_2NH$-,



R_{25} and R_{26} are independently selected from the group consisting of hydrogen, aryl, C_1-C_6 alkyl, and C_1-C_6 alkylaryl; or a pharmaceutically acceptable salt, solvate or prodrug thereof.

3. (Previously presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-tert-butoxycarbonylamino-1-ethyl]-3-butyl-5-(3-diethylamino-1-propoxy)benzimidazole.

4. (Previously presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-amino-1-ethyl]-3-butyl-5-(3-diethylamino-1-propoxy)benzimidazole Trihydrochloride.

5. (Previously presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-tert-butoxycarbonylamino-1-ethyl]-3-butyl-6-(3-diethylamino-1-propoxy)benzimidazole.

6. (Previously presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-amino-1-ethyl]-3-butyl-6-(3-diethylamino-1-propoxy)benzimidazole.

7. (Previously presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-tert-butoxycarbonylamino-1-ethyl]-6-(3-diethylamino-1-propoxy)benzimidazole.

8. (Previously presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-amino-1-ethyl]-6-(3-diethylamino-1-propoxy)benzimidazole.

9. (Previously presented) The compound of claim 1, wherein the compound is 2-[2-(3-Benzyloxyphenyl)-1-(tert-butoxycarbonylamino)-1-ethyl]-3-butyl-5-(3-diethylamino-1-propoxy)benzimidazole.

10. (Previously presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Ethoxyphenyl)-1-(tert-butoxycarbonylamino)-1-ethyl]-3-butyl-5-(3-diethylamino-1-propoxy)benzimidazole.

11. (Previously presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-(4-Chloro)phenethoxy)phenyl)-1-(tert-butoxycarbonylamino)-1-ethyl]-3-butyl-5-(3-diethylamino-1-propoxy)benzimidazole.

12. (Previously presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-(tert-butoxycarbonylamino)-1-ethyl]-3-(3-diethylamino-1-propyl)-5-(3-diethylamino-1-propoxy)benzimidazole.

13. (Previously presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-(tert-butoxycarbonylamino)-1-ethyl]-3-ethyl-5-(3-diethylamino-1-propoxy)benzimidazole.

14. (Previously presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-amino-1-ethyl]-3-(3-diethylamino-1-propyl)-5-(3-diethylamino-1-propoxy)benzimidazole.

15. (Previously presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-(tert-butoxycarbonylamino)-1-ethyl]-3-benzyl-5-(3-diethylamino-1-propoxy)benzimidazole.

16. (Previously presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-amino-1-ethyl]-3-benzyl-5-(3-diethylamino-1-propoxy)benzimidazole.

17. (Previously presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-(tert-butoxycarbonylamino)-1-ethyl]-3-propyl-5-(3-diethylamino-1-propoxy)benzimidazole

18. (Previously presented) The compound of claim 1, wherein the compound is 2-[(1R)-2-(4-Benzyloxyphenyl)-1-amino-1-ethyl]-3-propyl-5-(3-diethylamino-1-propoxy)benzimidazole.

19. (Original) A pharmaceutical composition comprising the compound of Formula (I) as claimed in claim 1, and one or more pharmaceutically acceptable carriers, excipients, or diluents.

20. (Previously Presented) The pharmaceutical composition of ~~to~~ claim 19, in the form of an oral dosage or parenteral dosage unit.

21. (Original) The pharmaceutical composition of claim 19, wherein said compound is administered as a dose in a range from about 0.01 to 500 mg/kg of body weight per day.

22. (Original) The pharmaceutical composition of claim 19, wherein said compound is administered as a dose in a range from about 0.1 to 200 mg/kg of body weight per day.

23. (Original) The pharmaceutical composition of claim 19, wherein said compound is administered as a dose in a range from about 0.1 to 100 mg/kg of body weight per day.

24. (Original) The pharmaceutical composition of claim 19, further comprising one or more therapeutic agents selected from the group consisting of alkylating agents, antimetabolites, plant alkaloids, antibiotics, hormones, biologic response modifiers, analgesics, NSAIDs, DMARDs, glucocorticoids, sulfonylureas, biguanides, insulin, cholinesterase inhibitors, antipsychotics, antidepressants, and anticonvulsants.

25. (Canceled)

26. (Canceled)

27. (Canceled)

28. (Canceled)

29. (Canceled)

30. (Canceled)

31. (Currently Amended) ~~The method of claim 28,~~ A method of treating RAGE mediated human diseases comprising administration to a human in need thereof a therapeutically effective amount of a compound of Formula (I) as claimed in claim 1, wherein a therapeutically effective amount comprises sufficient compound to at least partially inhibit the binding of a physiological ligand to the RAGE receptor, and wherein the RAGE mediated human disease comprises acute and/or chronic inflammation.

32. (Currently Amended) ~~The method of claim 28,~~ A method of treating RAGE mediated human diseases comprising administering to a human in need thereof a therapeutically effective amount of a compound of Formula (I) as claimed in claim 1, wherein a therapeutically effective amount comprises sufficient compound to at least partially inhibit the binding of a physiological ligand to the RAGE receptor, and wherein the RAGE mediated human disease comprises abnormal vascular permeability.

33. (Currently Amended) ~~The method of claim 28,~~ A method of treating RAGE mediated human diseases comprising administering to a human in need thereof a therapeutically effective amount of a compound of Formula (I) as claimed in claim 1, wherein a therapeutically effective amount comprises sufficient compound to at least partially inhibit the binding of a physiological ligand to the RAGE receptor, and wherein the RAGE mediated human disease comprises nephropathy.

34. (Currently Amended) ~~The method of claim 28,~~ A method of treating RAGE mediated human diseases comprising administering to a human in need thereof a therapeutically effective amount of a compound of Formula (I) as claimed in claim 1, wherein a therapeutically effective amount comprises sufficient compound to at least

partially inhibit the binding of a physiological ligand to the RAGE receptor, and wherein the RAGE mediated human disease comprises atherosclerosis.

35. (Currently Amended) ~~The method of claim 28,~~ A method of treating RAGE mediated human diseases comprising administering to a human in need thereof a therapeutically effective amount of a compound of Formula (I) as claimed in claim 1, wherein a therapeutically effective amount comprises sufficient compound to at least partially inhibit the binding of a physiological ligand to the RAGE receptor, and wherein the RAGE mediated human disease comprises retinopathy.

36. (Currently Amended) ~~The method of claim 28,~~ A method of treating RAGE mediated human diseases comprising administering to a human in need thereof a therapeutically effective amount of a compound of Formula (I) as claimed in claim 1, wherein a therapeutically effective amount comprises sufficient compound to at least partially inhibit the binding of a physiological ligand to the RAGE receptor, and wherein the RAGE mediated human disease comprises Alzheimer's disease.

37. (Currently Amended) ~~The method of claim 28,~~ A method of treating RAGE mediated human diseases comprising administering to a human in need thereof a therapeutically effective amount of a compound of Formula (I) as claimed in claim 1, wherein a therapeutically effective amount comprises sufficient compound to at least partially inhibit the binding of a physiological ligand to the RAGE receptor, and wherein the RAGE mediated human disease comprises erectile dysfunction.

38. (Canceled)

39. (Previously presented) The compound of claim 1, wherein R_4 is

a) –aryl;

b) -C_{1-6} alkyl;

c) -C_{1-6} alkylaryl; or

d) -C_{1-6} alkoxyaryl.